UBS Group’s Cyclerion Therapeutics CYCN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.3K | Sell |
9,727
-3,274
| -25% | -$9.53K | ﹤0.01% | 6902 |
|
|
2025
Q1 | $32.5K | Buy |
13,001
+3,334
| +34% | +$8.34K | ﹤0.01% | 6592 |
|
|
2024
Q4 | $31.1K | Buy |
9,667
+9,522
| +6,567% | +$30.7K | ﹤0.01% | 6350 |
|
|
2024
Q3 | $376 | Sell |
145
-2,561
| -95% | -$6.64K | ﹤0.01% | 7751 |
|
|
2024
Q2 | $6.22K | Buy |
2,706
+182
| +7% | +$419 | ﹤0.01% | 6780 |
|
|
2024
Q1 | $8.08K | Buy |
2,524
+296
| +13% | +$947 | ﹤0.01% | 6175 |
|
|
2023
Q4 | $7.46K | Buy |
2,228
+1,952
| +707% | +$6.54K | ﹤0.01% | 6416 |
|
|
2023
Q3 | $944 | Buy |
276
+90
| +48% | +$308 | ﹤0.01% | 7068 |
|
|
2023
Q2 | $766 | Sell |
186
-14,061
| -99% | -$57.9K | ﹤0.01% | 7027 |
|
|
2023
Q1 | $6.18K | Sell |
14,247
-3,965
| -22% | -$1.72K | ﹤0.01% | 6852 |
|
|
2022
Q4 | $12K | Buy |
+18,212
| New | +$12K | ﹤0.01% | 7131 |
|
|
2022
Q2 | – | Sell |
-3,645
| Closed | -$4K | – | 9314 |
|
|
2022
Q1 | $4K | Buy |
+3,645
| New | +$4K | ﹤0.01% | 8225 |
|
|
2021
Q4 | – | Sell |
-3,544
| Closed | -$11K | – | 9149 |
|
|
2021
Q3 | $11K | Buy |
3,544
+3,274
| +1,213% | +$10.2K | ﹤0.01% | 6728 |
|
|
2021
Q2 | $1K | Sell |
270
-4,412
| -94% | -$16.3K | ﹤0.01% | 8025 |
|
|
2021
Q1 | $13K | Sell |
4,682
-735
| -14% | -$2.04K | ﹤0.01% | 6704 |
|
|
2020
Q4 | $17K | Buy |
5,417
+5,010
| +1,231% | +$15.7K | ﹤0.01% | 6035 |
|
|
2020
Q3 | $2K | Sell |
407
-6,373
| -94% | -$31.3K | ﹤0.01% | 6760 |
|
|
2020
Q2 | $40K | Sell |
6,780
-7,382
| -52% | -$43.6K | ﹤0.01% | 5216 |
|
|
2020
Q1 | $38K | Sell |
14,162
-14,157
| -50% | -$38K | ﹤0.01% | 5147 |
|
|
2019
Q4 | $77K | Sell |
28,319
-10,630
| -27% | -$28.9K | ﹤0.01% | 5083 |
|
|
2019
Q3 | $471K | Buy |
38,949
+21,107
| +118% | +$255K | ﹤0.01% | 3778 |
|
|
2019
Q2 | $205K | Buy |
+17,842
| New | +$205K | ﹤0.01% | 4090 |
|